Literature DB >> 1458898

Adverse events of subcutaneous recombinant human erythropoietin therapy.

H Klinkmann1, R Schmidt, L Wieczorek, P Scigalla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1458898     DOI： 10.1159/000421456

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  2 in total

1.  The hypoxia-inducible factor prolyl hydroxylase inhibitor FG4592 promotes natriuresis through upregulation of COX2 in the renal medulla.

Authors:  Nan Guan; Min Zhang; Wei-Yuan Gong; Xiao-Yi Mao; Si-Si Yang; Chuan-Ming Hao
Journal:  Hypertens Res       Date:  2022-03-18       Impact factor: 3.872

Review 2.  Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Valeria Saglimbene; Dimitris Mavridis; Georgia Salanti; Jonathan C Craig; Marcello Tonelli; Natasha Wiebe; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.